NCT00394355View on ClinicalTrials.gov

Effects of Mometasone Furoate Dry Powder Inhaler, Fluticasone Propionate, and Montelukast on Bone Mineral Density in Asthmatics (Study P03418)

PHASE4CompletedINTERVENTIONAL
Enrollment

566

Participants

Timeline

Start Date

September 30, 2006

Primary Completion Date

October 31, 2009

Study Completion Date

October 31, 2009

Conditions
Asthma
Interventions
DRUG

mometasone furoate dry powder inhaler

400 mcg MF DPI via a breath-actuated, dry-powder inhaler and a placebo tablet given by mouth once daily in the evening for 1 year.

DRUG

mometasone furoate dry powder inhaler

200 mcg MF DPI via a breath-actuated, dry-powder inhaler and a placebo tablet given by mouth once daily in the evening for 1 year.

DRUG

fluticasone propionate hydrofluoroalkane (HFA)

250 mcg FP HFA given twice a day via a metered-dose inhaler and a placebo tablet given once daily in the evening for 1 year

DRUG

montelukast

10 mg given once daily in the evening by mouth for 1 year.

All Listed Sponsors
lead

Organon and Co

INDUSTRY

NCT00394355 - Effects of Mometasone Furoate Dry Powder Inhaler, Fluticasone Propionate, and Montelukast on Bone Mineral Density in Asthmatics (Study P03418) | Biotech Hunter | Biotech Hunter